Table 5.
IgG | |||||||
anti-Pfs25, μg/mL | anti-CSP, EU | ||||||
Conj. no. | Conjugate | Chains/Pfs25 (avg.) | Time of bleeding after last injection | Second inj. | Third inj. | Second inj. | Third inj. |
24 | NANP4-C/Pfs25-AH-Pfs25 | 9 | 1 week | 0.4 | 4 | 7 | 74 |
25 | NANP5-C/Pfs25-AH-Pfs25 | 4 | 1 week | – | 21 | – | 23 |
25 | NANP5-C/Pfs25-AH-Pfs25alum ads. | 4 | 1 week | 6 | 180 | 7 | 110 |
26 | NANP5-C/Pfs25-AH-Pfs25 | 5 | 1 week | 1 | 41 | 3 | 32 |
26 | NANP5-C/Pfs25-AH-Pfs25alum ads. | 5 | 1 week | 87 | 321 | 53 | 165 |
26 | NANP5-C/Pfs25-AH-Pfs25alum ads. | 5 | 3 months | 524 | – | 120 | – |
27 | NPNA5-C/Pfs25alum ads. | 5 | 1 week | 5 | 21 | 0.2 | 0.2 |
27 | NPNA5-C/Pfs25alum ads. | 5 | 3 months | 7 | 31 | 0.2 | 0.7 |
4 | NANP4-C/BSA | 8 | 1 week | – | – | 16 | 152 |
4 | NANP4-C/BSA | 8 | 3 months | – | – | 14 | 109 |
5 | NANP4-C/TT | 30 | 1 week | – | – | – | 132 |
5 | NANP4-C/TT | 30 | 3 months | – | – | – | 22 |
21 vs. 180, P = 0.01; 23 vs. 110, P = 0.01; 1 vs. 87 and 3 vs. 53, P < 0.001; 87 vs. 524, P = 0.004; 53 vs. 120, P = 0.03; 132 vs. 22, P = 0.01.